differentiated antibiotics

Cempra to Report First Quarter 2015 Financial Results

CHAPEL HILL, N.C., April 23, 2015 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report first quarter 2015 financial results after the close of U.S. financial markets on April 30, 2015. Cempra management will host a webcast and conference call at 4:30 p.m. EDT that day to discuss the financial results and provide a corporate update.
 

Cempra to Present at Two Upcoming Scientific Conferences

CHAPEL HILL, N.C., April 17, 2015 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 25th European Congress of Clinical Microbiology (ECCMID), in Copenhagen, Denmark, April 25-28 and the 2015 Pediatric Academic Societies (PAS) Annual Meeting in San Diego, April 25-28. Additional abstracts of solithromycin study results are being submitted for presentation at appropriate medical meetings.